Axel Hauschild, MD, University Hospital Schleswig-Holstein
Advertisement
Articles by Axel Hauschild, MD, University Hospital Schleswig-Holstein
Advertisement
Latest Updated Articles
Ipilimumab Dosing Significance in Adjuvant SettingPublished: October 12th 2020 | Updated:
Immune Checkpoint Inhibition in Stage IV MelanomaPublished: October 12th 2020 | Updated:
Triple Therapy for the Management of MelanomaPublished: October 12th 2020 | Updated:
COMBI-AD Trial 5-Year Analysis DataPublished: October 12th 2020 | Updated:
COMBI-i Trial Data UpdatesPublished: October 12th 2020 | Updated:
Checkpoint Blockade Trial Data UpdatesPublished: October 12th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5